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Chronic GVHD (cGVHD) is a major complication of allogeneic
hematopoietic stem cell transplantation (HSCT) and a leading
cause of non-relapse mortality. Extracorporeal photoimmune ther-
apy (ECP) has been used in retrospective and Phase II trials of
patients with cGVHD. The mechanism of action of ECP is elusive
but it appears to promote apoptosis and induce immune tolerance.
In this randomized, prospective study, we compared the safety and
efﬁcacy of ECP used in conjunction with conventional therapy
(calcineurin inhibitor 	 mycophenolate mofetil) and steroids to
conventional therapy alone in patients with steroid-refractory/
dependent/intolerant cutaneous cGVHD. In the ECP arm, pho-
topheresis was administered twice weekly for 12 weeks, then twice
monthly until Week 24; patients in the non-ECP arm could with-
draw from study after Week 12 if no beneﬁcial response was
observed or earlier if cGvHD worsened and enter a separate
extension study that included ECP. The primary efﬁcacy endpoint
was percent change from baseline in skin assessment score (Total
Skin Score; TSS) of 10 body regions graded from 0 to 5 (0 
normal, 1 discolored, 2  lichenoid, 3  thickened, 4  hide-
bound, 5  grades 3 or 4 with erythema; maximum score of 50) by
a trained blinded observer at week 12. All efﬁcacy analyses were
conducted on the modiﬁed intent-to-treat (MITT) patients who
had at least one treatment and one post-baseline TSS. Ninety-ﬁve
MITT patients (56 M, 39 F; median age  41 years) with steroid
refractory (n  12), intolerant (n  30) or dependent (n  57)
histologically-conﬁrmed cGVHD were randomized to receive
ECP and conventional therapy (n  48) or conventional therapy
alone (n  47). Study arms were balanced except for more GI
involvement in the non-ECP arm. Ninety-four percent in both
study arms had extensive cGVHD. 44 (92%) patients in the ECP
arm and 41 (87%) in the non-ECP arm completed the ﬁrst 12
weeks and those results are summarized in the table. ECP was
well-tolerated with a safety proﬁle consistent with previous studies.
Thus, ECP is effective in skin manifestations and steroid sparing in
steroid-refractory/dependent/intolerant chronic GVHD.
ECP
Non-
ECP
p
Value
Median Baseline TSS 9.4 9.2
Median % Improvement in TSS 14.5 10.4 0.510
Median % Improvement in pts
with TSS >-10 at baseline 21.9 12.1 0.418
% pts with >-50% Reduction in
Steroid Dose 29 14 0.089
% pts with >-50% Reduction in
Steroid Dose AND final
Steroid Dose < 10 mg/day 24 7 0.027
% pts with >-50% Reduction in
Steroid Dose AND >-25%
Reduction in TSS 10 0 0.040
% pts with CR and PR of Skin
by Investigator Assessment 40 10 0.0024
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RAPID EXPANSION OF ACUTE MYELOID LEUKEMIA-REACTIVE CYTO-
TOXIC T CELLS FROM CD8CD62L BLOOD LYMPHOCYTES OF HLA-
MATCHED HEALTHY DONORS IN VITRO
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Allogeneic cytotoxic T-lymphocyte (CTL) therapy in acute my-
eloid leukemia (AML) is hampered by the poor efﬁciency in grow-
ing leukemia-reactive CTLs from healthy donors in vitro. We
established an allogeneic mini-mixed lymphocyte-leukemia culture
(MLLC) approach by stimulating comparably small numbers (104/
well) of CD8 T cells isolated from peripheral blood of healthy
donors against primary AML blasts in 96-well plates. Prior to use,
CD8 T cells were immunomagnetically separated into a
CD62L(high) subset enriched for naive precursors and central
memory cells as well as a CD62L(low)/negative subset containing
effector memory cells. Mini-MLLCs were performed in seven
healthy donor-AML pairs that were matched for HLA class I
according to high-resolution sequence-based typing. Following 2
weekly re-stimulations with primary AML blasts, mini-MLLC
responder populations were tested using split-well IFN-gamma
ELISPOT assay. AML-reactive CD8 T-cell responders were
obtained from all 7 donor-AML pairs with the majority of reactive
cultures originally seeded with CD62L(high) cells. In 4 out of 7
pairs most MLLC responder populations recognized AML blasts,
but not Epstein-Barr virus transformed B-lymphoblastoid cell lines
of donor and patient origin. This leukemia reactivity was restricted
by various HLA class I alleles. Representative mini-MLLC re-
sponders demonstrated strong cytotoxicity against AML blasts in
51Chromium-release assay. Cross-reactivity testing identiﬁed an
HLA-A*0201-restricted CTL population that showed much stron-
ger recognition of AML blasts compared to their non-malignant
monocytic counterparts. This CTL did not recognize recipient-
derived primary ﬁbroblasts or other hematopoietic cells suggesting
a leukemia-associated rather than a minor histocompatibility anti-
gen as the target structure. Several MLLC-derived CTL popula-
tions expressed unique T cell receptor Vbeta chains consistent with
clonal derivation from AML-reactive precursors. Multiple CTL
responders reached a cell yield exceeding 108 by 6 to 10 weekly
re-stimulations with AML blasts. Our results suggest that in
healthy individuals most AML-reactive CD8 CTLs originate
from the CD62L(high) peripheral blood subpopulation contain-
ing naive precursor and central memory T cells. This mini-MLLC
approach should allow the expansion of AML-reactive CD8
CTLs from HLA-matched healthy donors to cell numbers sufﬁ-
cient for antigen identiﬁcation strategies or adoptive immunother-
apy trials.
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AN INTEGRATED GENETIC-PROTEIN ANALYSIS OF THE TNF-FAMILY
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Although the major cause of morbidity and treatment-related
mortality (TRM) after allogeneic HSCT is GVHD, there is no
predictive laboratory test for GVHD. Because tumor necrosis
factor- (TNF) plays an important role in GVHD pathogenesis we
tested the hypothesis that elevations in TNF levels on day 7 would
predict the development of signiﬁcant GVHD and treatment-
related mortality (TRM). We measured soluble TNF receptor 1
(TNFR1) as a surrogate for TNF because TNF circulates as a
ligand-receptor complex. We studied samples obtained under in-
formed consent from 438 patients undergoing allogeneic HSCT
following myeloablative conditioning at the University of Michi-
gan between 2000 and 2005. The median age of the patients was
42y (range 0-65y). The distribution of donors by degree of HLA-
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